{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:28:23Z","timestamp":1793946503523,"version":"4.8.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.critrevonc.2026.105504","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T15:45:55Z","timestamp":1785167155000},"page":"105504","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Circulating tumour DNA and molecular residual disease in oesophageal cancer: Clinical readiness, evidence gaps and trial-ready applications"],"prefix":"10.1016","volume":"226","author":[{"given":"Yu-Qi","family":"Meng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Tian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gengyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Ping","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ming","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105504_bib1","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41586-023-05776-4","article-title":"Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA","volume":"616","author":"Abbosh","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105504_bib2","doi-asserted-by":"crossref","first-page":"393","DOI":"10.6004\/jnccn.2023.0019","article-title":"Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology","volume":"21","author":"Ajani","year":"2023","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"10.1016\/j.critrevonc.2026.105504_bib3","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","article-title":"Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4)","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2026.105504_bib4","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1053\/j.gastro.2019.10.039","article-title":"Circulating tumor DNA analysis for detection of minimal residual disease after chemoradiotherapy for localized esophageal cancer","volume":"158","author":"Azad","year":"2020","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105504_bib5","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jtcvs.2018.09.136","article-title":"Patterns and risk of recurrence in patients with esophageal cancer with a pathologic complete response after chemoradiotherapy followed by surgery","volume":"157","author":"Barbetta","year":"2019","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.critrevonc.2026.105504_bib6","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2026.105504_bib7","first-page":"9.15.1","article-title":"Genetic tests: clinical validity and clinical utility","volume":"81","author":"Burke","year":"2014","journal-title":"Curr. Protoc. Hum. Genet."},{"key":"10.1016\/j.critrevonc.2026.105504_bib8","doi-asserted-by":"crossref","DOI":"10.1093\/dote\/doab046","article-title":"Clinical utility and applicability of circulating tumor DNA testing in esophageal cancer: a systematic review and meta-analysis","volume":"35","author":"Chidambaram","year":"2022","journal-title":"Dis. Esophagus"},{"key":"10.1016\/j.critrevonc.2026.105504_bib9","unstructured":"ClinicalTrials.gov, 2026a. An Exploratory Study of ctDNA-MRD in Predicting the Efficacy of Esophageal Squamous Cell Carcinoma. ClinicalTrials.gov identifier: NCT05759325. Status: Not Yet Recruiting. (accessed 8 June 2026). https:\/\/clinicaltrials.gov\/study\/NCT05759325."},{"key":"10.1016\/j.critrevonc.2026.105504_bib10","series-title":"Circulating Tumor DNA MRD-Guided Adjuvant Therapy for Curatively Resected Locally Advanced Esophageal Squamous Cell Carcinoma","author":"ClinicalTrials.gov","year":"2026"},{"key":"10.1016\/j.critrevonc.2026.105504_bib11","series-title":"ClinicalTrials","article-title":"Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer","author":"ClinicalTrials.gov","year":"2026"},{"key":"10.1016\/j.critrevonc.2026.105504_bib12","series-title":"Individualized Tumor-Informed CtDNA Analysis for Monitoring Postoperative Recurrence in ESCC (NEOCRTEC2401). ClinicalTrials","author":"ClinicalTrials.gov","year":"2026"},{"key":"10.1016\/j.critrevonc.2026.105504_bib13","series-title":"Liquid Biopsies in Esophageal Cancer","author":"ClinicalTrials.gov","year":"2026"},{"key":"10.1016\/j.critrevonc.2026.105504_bib14","series-title":"Minimally Residual of Esophageal Cancer 001","author":"ClinicalTrials.gov","year":"2026"},{"key":"10.1016\/j.critrevonc.2026.105504_bib15","series-title":"MRD-Guided Consolidation Therapy Following Definitive Radiotherapy in Esophageal Cancer","author":"ClinicalTrials.gov","year":"2026"},{"key":"10.1016\/j.critrevonc.2026.105504_bib16","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41586-023-06225-y","article-title":"Practical recommendations for using ctDNA in clinical decision making","volume":"619","author":"Cohen","year":"2023","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105504_bib17","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s43556-025-00310-6","article-title":"Circulating tumor DNA as a marker of molecular residual disease in resected esophageal squamous cell carcinoma","volume":"6","author":"Fang","year":"2025","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.critrevonc.2026.105504_bib18","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1001\/jamaoncol.2019.1838","article-title":"Assessment of molecular relapse detection in early-stage breast cancer","volume":"5","author":"Garcia-Murillas","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2026.105504_bib19","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1097\/JS9.0000000000001479","article-title":"Comparative investigation of neoadjuvant immunotherapy versus adjuvant immunotherapy in perioperative patients with cancer: a global-scale, cross-sectional, and large-sample informatics study","volume":"110","author":"Guo","year":"2024","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.critrevonc.2026.105504_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011040","article-title":"Immune-related adverse events of neoadjuvant immunotherapy in patients with perioperative cancer: a machine-learning-driven, decade-long informatics investigation","volume":"13","author":"Guo","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105504_bib21","series-title":"Human Genome Epidemiology: A Scientific Foundation for Using Genetic Information to Improve Health and Prevent Disease","first-page":"217","article-title":"ACCE: a model process for evaluating data on emerging genetic tests","author":"Haddow","year":"2004"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105504_bib22","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s44276-025-00158-x","article-title":"Circulating tumor DNA monitoring detects minimal residual disease and predicts outcomes in patients with esophageal adenocarcinoma or squamous cell carcinoma after esophagectomy","volume":"3","author":"Hu","year":"2025","journal-title":"BJC Rep."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105504_bib23","doi-asserted-by":"crossref","DOI":"10.1200\/PO.22.00420","article-title":"Analysis of circulating tumor DNA to predict risk of recurrence in patients with esophageal and gastric cancers","author":"Huffman","year":"2022","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105504_bib24","doi-asserted-by":"crossref","unstructured":"Iwaya, T., Endo, F., Yaegashi, M., Sasaki, N., Fujisawa, R., Hiraki, H., et al., 2020. Frequent tumor burden monitoring of esophageal squamous cell carcinoma with circulating tumor DNA using individually designed digital PCR. medRxiv [preprint]. https:\/\/doi.org\/10.1101\/2020.05.01.20087106.","DOI":"10.1101\/2020.05.01.20087106"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105504_bib25","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12943-025-02332-8","article-title":"Perioperative nivolumab and chemotherapy in locally advanced squamous cell carcinoma of the oesophagus: a randomized multicentre phase 2 study with circulating tumor DNA dynamics monitoring","volume":"24","author":"Jiao","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105504_bib26","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105504_bib27","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1245\/s10434-020-09219-6","article-title":"Pretreatment primary tumor stage is a risk factor for recurrence in patients with esophageal squamous cell carcinoma who achieve pathological complete response after neoadjuvant chemoradiotherapy","volume":"28","author":"La Mendola","year":"2021","journal-title":"Ann. Surg. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105504_bib28","doi-asserted-by":"crossref","DOI":"10.1200\/PO.24.00288","article-title":"Circulating tumor DNA as a prognostic biomarker for recurrence in patients with locoregional esophagogastric cancers with a pathologic complete response","author":"Lander","year":"2024","journal-title":"JCO Precis. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105504_bib29","doi-asserted-by":"crossref","DOI":"10.1111\/1759-7714.70017","article-title":"Exploring the clinical value of perioperative ctDNA-based detection of molecular residual disease in patients with esophageal squamous cell carcinoma","volume":"16","author":"Li","year":"2025","journal-title":"Thorac. Cancer"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105504_bib30","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1038\/s44321-024-00115-0","article-title":"Ultra-sensitive molecular residual disease detection through whole genome sequencing with single-read error correction","volume":"16","author":"Li","year":"2024","journal-title":"EMBO Mol. Med."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105504_bib31","article-title":"ctDNA detects residual disease after neoadjuvant chemoradiotherapy and guides adjuvant therapy in esophageal squamous cell carcinoma","volume":"6","author":"Liu","year":"2025","journal-title":"Cell. Rep. Med."},{"key":"10.1016\/j.critrevonc.2026.105504_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtcvs.2026.04.014","article-title":"Postoperative molecular residual disease status refines recurrence risk stratification beyond pathologic response after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma","author":"Liu","year":"2026","journal-title":"J. Thorac. Cardiovasc. Surg."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105504_bib33","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.bbrc.2016.02.011","article-title":"Noninvasive diagnosis and monitoring of mutations by deep sequencing of circulating tumor DNA in esophageal squamous cell carcinoma","volume":"471","author":"Luo","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105504_bib34","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.70242","article-title":"Circulating tumor DNA informs clinical practice in patients with recurrent\/metastatic gastroesophageal cancers","volume":"132","author":"Mehta","year":"2026","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2026.105504_bib35","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1053\/j.gastro.2022.05.054","article-title":"The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040: new estimates from GLOBOCAN 2020","volume":"163","author":"Morgan","year":"2022","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105504_bib36","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1001\/jamasurg.2023.4395","article-title":"Circulating tumor DNA dynamics as prognostic markers in locally advanced and metastatic esophageal squamous cell carcinoma","volume":"158","author":"Ng","year":"2023","journal-title":"JAMA Surg."},{"key":"10.1016\/j.critrevonc.2026.105504_bib37","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.annonc.2022.07.003","article-title":"Oesophageal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Obermannova","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105504_bib38","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41571-024-00967-y","article-title":"Minimal residual disease as a target for liquid biopsy in patients with solid tumours","volume":"22","author":"Pantel","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105504_bib39","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105504_bib40","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1470-2045(15)00040-6","article-title":"Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial","volume":"16","author":"Shapiro","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105504_bib41","article-title":"Genomic alterations and dynamic molecular residual disease monitoring predict pathological response to neoadjuvant chemoimmunotherapy in esophageal squamous cell carcinoma","volume":"17","author":"Shen","year":"2026","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105504_bib42","doi-asserted-by":"crossref","first-page":"8515","DOI":"10.1097\/JS9.0000000000003017","article-title":"Circulating tumor DNA as a biomarker for progression and survival in esophageal cancer after neoadjuvant therapy and esophagectomy: a systematic review and meta-analysis","volume":"111","author":"Shen","year":"2025","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.critrevonc.2026.105504_bib43","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer","volume":"386","author":"Tie","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105504_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1330928","article-title":"Minimal residual disease guided radical chemoradiotherapy combined with immunotherapy after neoadjuvant immunochemotherapy followed by adjuvant immunotherapy for esophageal squamous cell cancer (ECMRD-001): a study protocol for a prospective cohort study","volume":"14","author":"Wang","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105504_bib45","article-title":"Circulating tumor DNA predicts prognosis at different time points in patients with esophageal cancer: a systematic review and meta-analysis","volume":"15","author":"Wang","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105504_bib46","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1016\/S0140-6736(24)02226-8","article-title":"Oesophageal cancer","volume":"404","author":"Yang","year":"2024","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105504_bib47","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12943-024-02006-x","article-title":"Minimal residual disease profiling predicts pathological complete response in esophageal squamous cell carcinoma","volume":"23","author":"Yue","year":"2024","journal-title":"Mol. Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105504_bib48","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.1097\/JS9.0000000000001373","article-title":"Association between plasma circulating tumor DNA and the prognosis of esophageal cancer patients: a meta-analysis","volume":"110","author":"Zhang","year":"2024","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.critrevonc.2026.105504_bib49","series-title":"Application of high-throughput sequencing-based cfDNA liquid biopsy technology in tumour diagnosis and prognostic prediction [doctoral dissertation, in Chinese]","author":"Zhu","year":"2024"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003914?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003914?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:37:32Z","timestamp":1793943452000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826003914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":49,"alternative-id":["S1040842826003914"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105504","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Circulating tumour DNA and molecular residual disease in oesophageal cancer: Clinical readiness, evidence gaps and trial-ready applications","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105504","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105504"}}